- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04781140
Bewertung von SPN-812 (Viloxazin-Kapsel mit verlängerter Freisetzung) bei Kindern im Vorschulalter mit ADHS
Eine randomisierte, doppelblinde, multizentrische, placebokontrollierte Parallelgruppenstudie der Phase 4 zur Wirksamkeit und Sicherheit von SPN-812 bei Kindern im Vorschulalter (4 bis 5 Jahre) mit Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS). )
This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
This is a randomized, double-blind, placebo-controlled, multicenter, 2-arm (1:1), parallel-group, efficacy and safety/tolerability fixed-dose study of SPN-812 in preschool-age children (4 to 5 years old) with ADHD. Participants will be screened for eligibility for up to 4 weeks. Eligible participants will be treated with study medication for 6 weeks. The total duration of the study is up to 10 weeks.
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 4
Kontakte und Standorte
Studienkontakt
- Name: Olivia Elbaum
- Telefonnummer: 301-838-2500
- E-Mail: clinicaltrials@supernus.com
Studienorte
-
-
Alabama
-
Saraland, Alabama, Vereinigte Staaten, 36571
- Rekrutierung
- The Center for Clinical Trials, Inc.
-
Kontakt:
- Telefonnummer: 251-341-7021
- E-Mail: info@thecenterforclinicaltrials.com
-
-
Arkansas
-
Fayetteville, Arkansas, Vereinigte Staaten, 72703
- Zurückgezogen
- Preferred Research Partners-NWA, LLC
-
Little Rock, Arkansas, Vereinigte Staaten, 72211
- Rekrutierung
- Preferred Research Partners, Inc.
-
Kontakt:
- Telefonnummer: 501-553-9987
- E-Mail: info@preferredresearchpartners.com
-
-
California
-
Anaheim, California, Vereinigte Staaten, 92805
- Rekrutierung
- Advanced Research Center (ARC), Inc.
-
Kontakt:
- Telefonnummer: 714-999-6688
- E-Mail: contact@arctrials.com
-
Encino, California, Vereinigte Staaten, 91316
- Zurückgezogen
- Wake Research-Pharmacology Research Institute (WR-PRI), LLC [Encino]
-
Garden Grove, California, Vereinigte Staaten, 92844
- Beendet
- National Institute of Clinical Research (PICR)
-
Imperial, California, Vereinigte Staaten, 92251
- Rekrutierung
- Sun Valley Research Center
-
Kontakt:
- Telefonnummer: 760-545-0123
- E-Mail: svrcinfo@sunvalleyb.com
-
Long Beach, California, Vereinigte Staaten, 90807
- Rekrutierung
- Alliance Research
-
Kontakt:
- Telefonnummer: 562-548-8500
- E-Mail: Research@asclepes.com
-
Newport Beach, California, Vereinigte Staaten, 92660
- Zurückgezogen
- Wake Research-Pharmacology Research Institute (WR-PRI), LLC [Newport Beach]
-
-
Colorado
-
Centennial, Colorado, Vereinigte Staaten, 80112
- Rekrutierung
- IMMUNOe Research Centers
-
Kontakt:
- Telefonnummer: 303-771-9000
- E-Mail: verosinfo@veroshealth.com
-
Kontakt:
- Telefonnummer: 303-773-9000
-
-
Florida
-
Clermont, Florida, Vereinigte Staaten, 34711
- Zurückgezogen
- Vertex Clinical Research, LLC
-
Coral Gables, Florida, Vereinigte Staaten, 33134
- Rekrutierung
- Luna Research Center
-
Kontakt:
- Telefonnummer: 305-613-7761
-
Gainesville, Florida, Vereinigte Staaten, 32607
- Beendet
- Sarkis Clinical Trials
-
Jacksonville, Florida, Vereinigte Staaten, 32256
- Rekrutierung
- Clinical Neuroscience Solutions, Inc.
-
Kontakt:
- Telefonnummer: 904-281-5757
-
Lakeland, Florida, Vereinigte Staaten, 33803
- Beendet
- Accel Research Sites - Lakeland CRU
-
Miami, Florida, Vereinigte Staaten, 33155
- Rekrutierung
- Avantis Clinical Research LLC
-
Kontakt:
- Telefonnummer: 305-515-9006
- E-Mail: info@avantisclinicalresearch.com
-
Orange City, Florida, Vereinigte Staaten, 32763
- Rekrutierung
- Medical Research Group of Central Florida
-
Kontakt:
- Telefonnummer: 386-775-7627
-
Orlando, Florida, Vereinigte Staaten, 32801
- Rekrutierung
- Clinical Neuroscience Solutions, Inc.
-
Kontakt:
- Telefonnummer: 407-425-5100
- E-Mail: orlinfo@cnshealthcare.com
-
Orlando, Florida, Vereinigte Staaten, 32803
- Rekrutierung
- APG Research LLC
-
Kontakt:
- Telefonnummer: 166 407-423-7149
- E-Mail: kkenworthyapg@gmail.com
-
Kontakt:
- Telefonnummer: 165 407-423-7149
-
Tamarac, Florida, Vereinigte Staaten, 33321
- Rekrutierung
- D&H Tamarac Research Center
-
Kontakt:
- Telefonnummer: 786-375-6210
- E-Mail: info@dhnrc.com
-
Virginia Gardens, Florida, Vereinigte Staaten, 33166
- Rekrutierung
- Hope Research Network, LLC.
-
Kontakt:
- Telefonnummer: 786-953-8858
- E-Mail: info@hoperesearchnetwork.com
-
Winter Park, Florida, Vereinigte Staaten, 32789
- Rekrutierung
- Pediatric Neurology and Epilepsy Specialists
-
Kontakt:
- Telefonnummer: 121 407-293-1122
- E-Mail: ARiveraDelValle@pediatricneurologyandepilepsy.com
-
Kontakt:
- Telefonnummer: 126 407-293-1122
- E-Mail: DHubert@pediatricneurologyandepilepsy.com
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30328
- Rekrutierung
- Clinical Integrative Research Center of Atlanta
-
Kontakt:
- Telefonnummer: 678-705-7341
-
Atlanta, Georgia, Vereinigte Staaten, 30318
- Rekrutierung
- Advanced Discovery Research LLC
-
Kontakt:
- Telefonnummer: 470-777-8839
- E-Mail: contact@advdiscovery.com
-
Decatur, Georgia, Vereinigte Staaten, 30030
- Rekrutierung
- CenExcel iResearch, LLC
-
Kontakt:
- Telefonnummer: 404-537-1281
-
Savannah, Georgia, Vereinigte Staaten, 31405
- Rekrutierung
- CenExel iResearch, LLC.
-
Kontakt:
- Telefonnummer: 912-744-0800
-
-
Indiana
-
Evansville, Indiana, Vereinigte Staaten, 47715
- Beendet
- Qualmedica Research, LLC.
-
-
Kentucky
-
Bardstown, Kentucky, Vereinigte Staaten, 40004
- Rekrutierung
- Kentucky Pediatric/Adult Research
-
Kontakt:
- Telefonnummer: 502-349-1569
- E-Mail: kpar@kpar.us
-
Owensboro, Kentucky, Vereinigte Staaten, 42301
- Beendet
- Qualmedica Research, LLC.
-
-
Louisiana
-
New Orleans, Louisiana, Vereinigte Staaten, 70115
- Beendet
- DelRicht Research (Touro Medical Center)
-
Prairieville, Louisiana, Vereinigte Staaten, 70769
- Rekrutierung
- DelRicht Research
-
Kontakt:
- Telefonnummer: 225-412-0316
- E-Mail: info@delricht.com
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21205
- Rekrutierung
- Kennedy Krieger Institute
-
Kontakt:
- Telefonnummer: 443-923-3850
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02445
- Rekrutierung
- Boston Children's Hospital
-
Kontakt:
- Telefonnummer: 617-919-6954
-
Kontakt:
- Telefonnummer: 617-355-1118
- E-Mail: benamin.mills@childrens.harvard.edu
-
-
Michigan
-
Bloomfield Hills, Michigan, Vereinigte Staaten, 48302
- Rekrutierung
- Neurobehavioral Medicine Group
-
Kontakt:
- Telefonnummer: 248-290-5400
- E-Mail: info@neurobmg.com
-
-
Mississippi
-
Flowood, Mississippi, Vereinigte Staaten, 39232
- Rekrutierung
- Precise Research Centers
-
Kontakt:
- Telefonnummer: 601-420-5812
-
-
Nevada
-
Las Vegas, Nevada, Vereinigte Staaten, 89128
- Rekrutierung
- Clinical Research of Southern Nevada, LLC.
-
Kontakt:
- Telefonnummer: 702-750-0000
- E-Mail: kluna.cpbm@gmail.com
-
-
New Jersey
-
Berlin, New Jersey, Vereinigte Staaten, 08009
- Zurückgezogen
- Hassman Research Institute
-
Irvington, New Jersey, Vereinigte Staaten, 07111
- Rekrutierung
- Med Clinical Research
-
Kontakt:
- Telefonnummer: 908-798-8373
- E-Mail: info@medclinicalresearch.com
-
Neptune City, New Jersey, Vereinigte Staaten, 07753
- Rekrutierung
- Jersey Shore University Medical Center
-
Kontakt:
- Telefonnummer: 732-897-3640
- E-Mail: andrew.layman@hmhn.org
-
-
New York
-
New York, New York, Vereinigte Staaten, 10028
- Zurückgezogen
- Icahn School of Medicine at Mount Sinai
-
-
North Carolina
-
Durham, North Carolina, Vereinigte Staaten, 27705
- Rekrutierung
- Duke University
-
Kontakt:
- Telefonnummer: 919-681-1100
-
-
Ohio
-
Cincinnati, Ohio, Vereinigte Staaten, 45229
- Rekrutierung
- Cincinnati Children's Hospital and Medical Center
-
Kontakt:
- Telefonnummer: 513-636-9763
- E-Mail: ADHDResearch@cchmc.org
-
West Chester, Ohio, Vereinigte Staaten, 45069
- Zurückgezogen
- CincyScience
-
-
Oregon
-
Gresham, Oregon, Vereinigte Staaten, 97030
- Rekrutierung
- Cyn3rgy Research
-
Kontakt:
- Telefonnummer: 503-907-2179
- E-Mail: support@cyn3rgy.com
-
-
Pennsylvania
-
Hershey, Pennsylvania, Vereinigte Staaten, 17033
- Rekrutierung
- Penn State Health Medical Group - Psychiatry and Behavioral Health
-
Kontakt:
- Telefonnummer: 287364 717-531-0003
- E-Mail: rmyers12@pennstatehealth.psu.edu
-
Kontakt:
- Telefonnummer: 717-531-5656
-
-
South Carolina
-
North Charleston, South Carolina, Vereinigte Staaten, 29405
- Rekrutierung
- Coastal Carolina Research Center
-
Kontakt:
- Telefonnummer: 843-856-3784
- E-Mail: CCRC@CoastalCarolinaResearch.com
-
Summerville, South Carolina, Vereinigte Staaten, 29486
- Rekrutierung
- Coastal Pediatric Research
-
Kontakt:
- Telefonnummer: 843-870-2225
- E-Mail: info.research@cpakids.com
-
-
Tennessee
-
Memphis, Tennessee, Vereinigte Staaten, 38119
- Rekrutierung
- Clinical Neuroscience Solutions, Inc.
-
Kontakt:
- Telefonnummer: 901-843-1045
-
-
Texas
-
Bellaire, Texas, Vereinigte Staaten, 77401
- Zurückgezogen
- Houston Clinical Trials, LLC.
-
Dallas, Texas, Vereinigte Staaten, 75230
- Beendet
- Javara
-
Plano, Texas, Vereinigte Staaten, 75093
- Rekrutierung
- AIM Trials, LLC
-
Kontakt:
- Telefonnummer: 469-364-8804
- E-Mail: info@aimtrials.com
-
Kontakt:
- Telefonnummer: 214-856-2778
-
The Woodlands, Texas, Vereinigte Staaten, 77381
- Rekrutierung
- Family Psych of The Woodlands
-
Kontakt:
- Telefonnummer: 281-367-1015
- E-Mail: info@woodlandspsych.com
-
-
Virginia
-
Petersburg, Virginia, Vereinigte Staaten, 23805
- Rekrutierung
- Clinical Research Partners, LLC
-
Kontakt:
- Telefonnummer: 804-921-9592
- E-Mail: Recruitment@ClinicalResearchRVA.com
-
Richmond, Virginia, Vereinigte Staaten, 23220
- Rekrutierung
- Virginia Commonwealth University, Virginia Treatment Center for Children
-
Kontakt:
- Telefonnummer: 804-628-8736
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Is male or female 4 years 0 months of age to less than or equal to 5 years 9 months of age at Visit 1 (Screening) and considered medically healthy.
- Subject's parent(s) or legal guardian(s)/representative(s) is (are) willing and able to provide written informed consent before completing any study related procedures.
- Has a primary diagnosis of ADHD according to DSM-IV-TR criteria and confirmed with the Kiddie Schedule for Affective Disorders and Schizophrenia - Present and Lifetime Version (K-SADS-PL).
- Has an ADHD-RS-IV-P Total Score of ≥ 28 (males) or ≥ 24 (females) at Visit 1 (Screening) and at Visit 2 (Baseline).
- Has a CGI-S score of ≥ 4 (moderate or worse) at Visit 1 (Screening) and at Visit 2 (Baseline).
- Has undergone an adequate course of non-pharmacologic treatment or is having symptoms severe enough to warrant pharmacologic treatment without prior non-pharmacologic treatment.
- Is participating in a structured group activity (e.g., preschool, kindergarten, sports, Sunday school, summer camp or childcare program) at least 2 days a week during study so as to assess symptoms and impairment in a setting outside the home.
- Has not initiated any behavioral intervention/therapy within 30 days of Visit 1 (Screening) and does not plan to initiate any new or discontinue any ongoing behavioral intervention/therapy during the study (e.g., subject is eligible if behavioral intervention/therapy is initiated 30 or more days prior to Visit 1 [Screening] and continues with a similar duration/frequency throughout their study).
- Subjects who are on ADHD medication at Visit 1 (Screening), but whose ADHD symptoms are not well controlled on current ADHD medication (e.g., meets Inclusion Criterion #4), meet all other inclusion/exclusion criteria, and discontinues ADHD medication at least 7 days prior to the day of Visit 2 (Baseline) are eligible to participate.
- Has no current condition in the opinion of the Investigator that could confound efficacy assessments, safety assessments or increase participant risk.
- Has lived with the same parent(s) or legal guardian(s) or has lived under a shared living arrangement (e.g., joint legal custody) for greater than or equal to 6 months prior to Visit 1 (Screening).
- Has a body weight ≥5th percentile for age and sex at Visit 1 (Screening) and Visit 2 (Baseline).
Exclusion Criteria:
- Has a diagnosis at Screening (per K-SADS-PL) of another psychiatric disorder that is considered to be the primary diagnosis rather than ADHD or has a comorbid psychiatric disorder secondary to ADHD that, in the opinion of the investigator (after consulting medical monitor), will likely interfere with study treatment adherence and/or impact study results.
- Has a current diagnosis of a major neurological disorder. The eligibility of those who have seizures, a history of seizure-like events (e.g., syncope, myoclonus, severe muscle spasms), a family history of seizure disorder (immediate family, i.e., sibling, parent), and/or febrile seizures will be assessed on a case-by-case basis after consulting the medical monitor.
- History of Bipolar Disorder diagnosed in a first degree relative.
- Has global development delay or intellectual disability by medical history.
- Has a current diagnosis of a significant (per Investigator's evaluation and/or judgement) systemic disease.
- Has body mass index > 95th percentile for the subject's age and sex at Visit 1 (Screening) or Visit 2 (Baseline).
- Has a mean resting systolic and diastolic blood pressure* that are both >95th percentile for age sex, and height and has a mean resting pulse rate* that is >95th percentile for age and sex (males: >117 bpm; females: >122 bpm) at Visit 1 (Screening) or Visit 2 (Baseline). * Note: The mean of three measurements while seated.
- Has a clinically significant electrocardiogram finding(s) at Visit 1 (Screening).
- Is currently taking SPN-812 for ADHD, has previously taken SPN-812 for ADHD, but discontinued due to a lack of efficacy or adverse reactions, or has history of allergic reaction, hypersensitivity or intolerance to viloxazine.
- Has an allergy to or cannot swallow pudding and applesauce and cannot swallow intact capsule whole.
- Has any food allergy, intolerance, restriction or special diet that, in the opinion of the Investigator, could contraindicate the subject's participation in the study.
- Has received any investigational drug within the longer of 30 days or 5 half-lives prior to Visit 2 (e.g., first dose of study medication).
- Has a positive urine drug test at Visit 1 (Screening). A positive test for amphetamines is allowed for subjects receiving a stimulant ADHD medication at Screening. The subject will be required to discontinue the stimulant for the duration of the study, beginning at least 7 days prior to Visit 2 (Baseline).
- Is using of prohibited concomitant medications including known CYP1A2 substrates (e.g., theophylline, melatonin) during the Screening Period or (anticipated) for the duration of the study.
- Any reason that, in the opinion of the Investigator, would prevent the subject from participating in the study.
- Has suicidal ideation ("Yes" indicated on C-SSRS question 4 or 5) or suicidal behavior ("Yes" indicated on C-SSRS for any suicidal behavior) within 6 months prior to or the day of Visit 1 (Screening) or has attempted suicide ("Yes" indicated on C-SSRS for lifetime).
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Placebo-Komparator: Placebo
Placebo, qd |
Placebo will be administered once daily |
|
Experimental: SPN-812
SPN-812, qd |
100mg SPN-812 will be administered once daily and compared to Placebo
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change from Baseline in the Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Total Score at End of Study (Week 6)
Zeitfenster: Baseline and Week 6
|
The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two subscales: inattention ("IA", 9 items) and hyperactivity-impulsivity ("H/I", 9 items).The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale, where 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. The sum of the ratings of all 18 items yields the raw Total score (range: 0-54; the higher the Total score, the more severe the ADHD symptoms). Post-baseline raw Total scores are converted to a change from baseline Total score. A lower change from baseline ADHD-RS-IV-P Total Score (<0) represents a better outcome. |
Baseline and Week 6
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change from Baseline in the Clinical Global Impression of Severity (CGI-S) Score at End of Study (Week 6)
Zeitfenster: Baseline and Week 6
|
The Clinical Global Impression of Severity (CGI-S) is a single item clinician-rated assessment of the severity of subject's condition (ADHD symptoms) in relation to the clinician's total experience with patients with ADHD. The CGI-S is evaluated on a 7-point scale with 1 = Normal, not at all ill, asymptomatic, 2 = Borderline Ill, 3 = Mildly Ill, 4 = Moderately Ill, 5 = Markedly Ill, 6 = Severely Ill, and 7 = Among the most extremely ill patients (the higher the score, the more severe the overall ADHD symptoms). Post-baseline (raw) CGI-S scores are converted to a change from baseline score. A lower change from baseline CGI-S score (<0) represents a better outcome. |
Baseline and Week 6
|
|
Clinical Global Impression of Change (CGI-C) Score at End of Study (Week 6)
Zeitfenster: Week 6
|
The Clinical Global Impression of Change (CGI-C) is a single item clinician-rated assessment of how much the subject's condition (ADHD) has improved, worsened or has not changed relative to his/her baseline state prior to the beginning of treatment. The CGI-C is rated on a 7-point scale from 1 to 7, where 1 = "very much improved", 2 = "much improved", 3 = "minimally improved", 4 = "no change", 5 = "minimally worse", 6 = "much worse", and 7 = "very much worse". A CGI-C score <4 represents a better outcome. |
Week 6
|
|
Change from Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Hyperactivity/Impulsivity Subscale Score at End of Study (Week 6)
Zeitfenster: Baseline and Week 6
|
The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two subscales: inattention ("IA", 9 items) and hyperactivity-impulsivity ("H/I" 9 items).The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale, where 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. The sum of the nine H/I items yields the raw H/I subscale score (range: 0-27; the higher the H/I subscale score, the more severe the H/I symptoms). Post-baseline raw H/I subscale scores are converted to a change from baseline score. A lower change from baseline H/I subscale score (<0) represents a better outcome. |
Baseline and Week 6
|
|
Change from Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Inattention Subscale Score at End of Study (Week 6)
Zeitfenster: Baseline and Week 6
|
The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two subscales: inattention ("IA", 9 items) and hyperactivity-impulsivity ("H/I" 9 items).The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale, where 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. The sum of the nine IA items yields the raw IA subscale score (range: 0-27; the higher the IA subscale score, the more severe the IA symptoms). Post-baseline raw IA subscale scores are converted to a change from baseline score. A lower change from baseline IA subscale score (<0) represents a better outcome. |
Baseline and Week 6
|
|
Clinical Global Impression of Severity (CGI-S) Responder Rate (percentage of subjects with CGI-S score of 1 or 2) at End of Study (Week 6)
Zeitfenster: Baseline and Week 6
|
The Clinical Global Impression of Severity (CGI-S) is a single item clinician-rated assessment of the severity of subject's condition (ADHD symptoms) in relation to the clinician's total experience with patients with ADHD. The CGI-S is evaluated on a 7-point scale with 1 = Normal, not at all ill, asymptomatic, 2 = Borderline Ill, 3 = Mildly Ill, 4 = Moderately Ill, 5 = Markedly Ill, 6 = Severely Ill, and 7 = Among the most extremely ill patients. The responder rate (percent) is calculated by dividing "the number of 'responders' (m)" by "the number of subjects analyzed at the respective Visit/Week (n)" and multiplying the product by 100. Responder Rate values range from 0 to 100%. A percent >50% represents a greater number of "responders" versus "non-responders". |
Baseline and Week 6
|
|
Clinical Global Impression of Change (CGI-C) Responder Rate (percentage of subjects with CGI-C score of 1 or 2) at End of Study (Week 6)
Zeitfenster: Week 6
|
The Clinical Global Impression of Change (CGI-C) is a single item clinician-rated assessment of how much the subject's condition (ADHD) has improved, worsened or has not changed relative to his/her baseline state prior to the beginning of treatment. The CGI-C is rated on a 7-point scale from 1 to 7, where 1 = "very much improved", 2 = "much improved", 3 = "minimally improved", 4 = "no change", 5 = "minimally worse", 6 = "much worse", and 7 = "very much worse". The responder rate (percent) is calculated by dividing "the number of 'responders' (m)" by "the number of subjects analyzed at the respective Visit/Week (n)" and multiplying the product by 100. Responder Rate values range from 0 to 100%. A percent >50% represents a greater number of "responders" versus "non-responders". |
Week 6
|
|
Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Responder Rate (percentage of subjects with ≥ 50% Reduction in Change from Baseline) at End of Study (Week 6)
Zeitfenster: Baseline and Week 6
|
The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two 9 item subscales: inattention and hyperactivity-impulsivity. The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale; 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. Sum of 18 ratings yields the Total score (range: 0-54; higher score represents severer symptoms). Percent reduction is calculated for the ADHD-RS-IV-P score: [("Post-baseline"-"Baseline")/"Baseline"] x 100; range: 0 to 100%; a "responder" is a subject with a 50% or greater reduction in change from baseline Total score. Responder rate (percent of responders) is calculated: ["number of 'responders' (m)"/ "number of subjects analyzed" (n)] X 100; range: 0 to 100%. A Responder Rate greater than 50%, represents more "responders" versus "nonresponders". |
Baseline and Week 6
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Joseph Hull, PhD, Supernus Pharmaceuticals, Inc.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 812P401
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .